Why the study?
Is serum high-molecular weight (HMW) adiponectin associated with the presence of coronary artery disease in patients with type 2 diabetes?
Is serum high-molecular weight (HMW) adiponectin associated with the presence of coronary artery disease in patients with type 2 diabetes?
Measuring high-molecular weight (HMW) adiponectin, particularly the HMW-to-total adiponectin ratio, may serve as a useful biomarker for evaluating coronary artery disease risk in patients with type 2 diabetes.
Answers are grounded in this paper and cite their sources.
Lower HMW adiponectin associated with CAD in diabetic men; leaves open biomarker utility pending prospective studies.
Adiponectin (Acrp30), an adipocyte-derived protein, exists in serum as a trimer, a hexamer, and a high-molecular weight (HMW) form, including 12-18 subunits. Because HMW adiponectin may be biologically active, we measured it in serum using a novel enzyme-linked immunosorbent assay (ELISA) confirmed by gel filtration chromatography that the ELISA detected mainly adiponectin with 12-18 subunits, and we compared HMW with total adiponectin concentration in patients with type 2 diabetes. We next investigated the relationship between serum HMW and coronary artery disease (CAD) in 280 consecutive type 2 diabetic patients, including 59 patients with angiographically confirmed CAD. Total adiponectin was measured in serum by a commercially available ELISA. Like serum total adiponectin, HMW adiponectin correlated positively with HDL cholesterol and negatively with triglyceride, insulin sensitivity, creatinine clearance, and circulating inflammatory markers. Total and HMW adiponectin were significantly higher in women than in men, as was the HMW-to-total adiponectin ratio. Serum HMW and the HMW-to-total adiponectin ratio were significantly lower in men with than without CAD (P < 0.05, respectively). In women, the ratio, but neither total nor HMW adiponectin, tended to be lower when CAD was present. In conclusion, determination of HMW adiponectin, especially relative to total serum adiponectin, is useful for evaluating CAD in type 2 diabetic patients.
No takes yet. Share an insight, caveat, or question.
Aso et al. (2006) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: